Ascendis Pharma A/S (ASND) Rating Lowered to Hold at BidaskClub

Share on StockTwits

Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Several other brokerages also recently commented on ASND. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research note on Tuesday, June 26th. They issued a “buy” rating and a $85.00 target price for the company. Wedbush restated an “outperform” rating and issued a $76.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, May 15th. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $79.00 to $81.00 and gave the stock an “overweight” rating in a research note on Thursday, August 30th. Canaccord Genuity started coverage on Ascendis Pharma A/S in a research note on Tuesday, August 7th. They issued a “buy” rating and a $81.00 target price for the company. Finally, Wells Fargo & Co raised their target price on Ascendis Pharma A/S from $83.00 to $88.00 and gave the stock an “outperform” rating in a research note on Thursday, August 30th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average target price of $77.25.

Shares of NASDAQ ASND opened at $68.20 on Friday. Ascendis Pharma A/S has a 52 week low of $26.30 and a 52 week high of $76.99. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -15.75 and a beta of 0.67.

Institutional investors and hedge funds have recently modified their holdings of the company. Quantitative Systematic Strategies LLC bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $361,000. Neuberger Berman Group LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $916,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at about $1,319,000. UBS Group AG boosted its position in shares of Ascendis Pharma A/S by 65.7% during the 1st quarter. UBS Group AG now owns 6,734 shares of the biotechnology company’s stock valued at $440,000 after acquiring an additional 2,670 shares during the last quarter. Finally, Eversept Partners LLC boosted its position in shares of Ascendis Pharma A/S by 98.5% during the 1st quarter. Eversept Partners LLC now owns 24,054 shares of the biotechnology company’s stock valued at $1,573,000 after acquiring an additional 11,936 shares during the last quarter. Hedge funds and other institutional investors own 95.29% of the company’s stock.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Dividend Stocks – Are They Right For You?

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply